ALL
The Adaptive Experience
The demographics of clonoSEQ-tested patients are consistent with overall disease demographics.
Who are the patients receiving clonoSEQ MRD testing in the real world?
The age and sex of U.S. patients with CLL, myeloma, or B-ALL who have been tested with clonoSEQ is representative of and consistent with the NCI Surveillance, Epidemiology, and End Results Program.1-3
clonoSEQ testing demographics by disease (2019 & 2020)
MM
CLL
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.
Citations
- Acute Lymphocytic Leukemia – Cancer Stat Facts. SEER. Accessed September 8, 2020. https://seer.cancer.gov/statfacts/html/alyl.html
- Chronic Lymphocytic Leukemia – Cancer Stat Facts. SEER. Accessed September 8, 2020. https://seer.cancer.gov/statfacts/html/clyl.html
- Myeloma – Cancer Stat Facts. SEER. Accessed September 8, 2020. https://seer.cancer.gov/statfacts/html/mulmy.html